Literature DB >> 30838240

Sustained Effect of Botulinum Neurotoxin in Myoclonus Owing to Epilepsia Partialis Continua.

Janis Rebecca Bedarf1, Milena Marek1, Christian G Bien2, Christian E Elger3, Sebastian Paus1.   

Abstract

BACKGROUND: Epilepsia partialis continua (EPC) is defined as continuous myoclonic jerking of a body part of cortical origin and often resembles a movement disorder. Unfortunately, anti-epileptic therapy is frequently ineffective. Currently, the effect of botulinum neurotoxin (BoNT) therapy in EPC is controversial.
METHODS: We analyzed case histories, treatment protocols, and video documentation of 5 patients with EPC, who received BoNT therapy in our movement disorders unit. The Unified Myoclonus Rating Scale was used to document treatment effects.
RESULTS: In all patients, BoNT treatment significantly reduced severity and frequency of myoclonus and led to pronounced improvement of speech and arm utilization, regardless of etiology or duration of EPC.
CONCLUSION: BoNT represents a safe, effective treatment in EPC, offering long-term abatement of myoclonus. The substantial functional profit may hint at mechanisms beyond local impairment of neuromuscular transmission, such as modulation of maladaptive cortical plasticity, as observed in dystonia and poststroke spasticity.

Entities:  

Keywords:  botulinum neurotoxin; epilepsia partialis continua; myoclonus; seizure

Year:  2015        PMID: 30838240      PMCID: PMC6353434          DOI: 10.1002/mdc3.12216

Source DB:  PubMed          Journal:  Mov Disord Clin Pract        ISSN: 2330-1619


  23 in total

1.  The Unified Myoclonus Rating Scale.

Authors:  Steven J Frucht; Sue E Leurgans; Mark Hallett; Stanley Fahn
Journal:  Adv Neurol       Date:  2002

2.  Botulinum toxin A improves involuntary limb movements in Rasmussen syndrome.

Authors:  Dora A Lozsadi; Ian K Hart; A Peter Moore
Journal:  Neurology       Date:  2004-04-13       Impact factor: 9.910

3.  Botulinum toxin treatment of facial myoclonus in suspected Rasmussen encephalitis.

Authors:  Nina Browner; Shaheda N Azher; Joseph Jankovic
Journal:  Mov Disord       Date:  2006-09       Impact factor: 10.338

4.  Botulinum toxin treatment of epilepsia partialis continua.

Authors:  Jun-Suk Kang; Karsten Krakow; Julia Roggendorf; Helmuth Steinmetz; Ruediger Hilker
Journal:  Mov Disord       Date:  2009-01-15       Impact factor: 10.338

Review 5.  Physiology of epilepsia partialis continua and subcortical mechanisms of status epilepticus.

Authors:  Renzo Guerrini
Journal:  Epilepsia       Date:  2009-12       Impact factor: 5.864

Review 6.  Management of patients with myoclonus: available therapies and the need for an evidence-based approach.

Authors:  Joke M Dijk; Marina A J Tijssen
Journal:  Lancet Neurol       Date:  2010-10       Impact factor: 44.182

7.  A proposed diagnostic scheme for people with epileptic seizures and with epilepsy: report of the ILAE Task Force on Classification and Terminology.

Authors:  J Engel
Journal:  Epilepsia       Date:  2001-06       Impact factor: 5.864

8.  Definition of drug resistant epilepsy: consensus proposal by the ad hoc Task Force of the ILAE Commission on Therapeutic Strategies.

Authors:  Patrick Kwan; Alexis Arzimanoglou; Anne T Berg; Martin J Brodie; W Allen Hauser; Gary Mathern; Solomon L Moshé; Emilio Perucca; Samuel Wiebe; Jacqueline French
Journal:  Epilepsia       Date:  2009-11-03       Impact factor: 5.864

Review 9.  Epilepsia partialis continua: semiology and differential diagnoses.

Authors:  Christian G Bien; Christian E Elger
Journal:  Epileptic Disord       Date:  2008-03       Impact factor: 1.819

Review 10.  Treatment options for epileptic myoclonus and epilepsy syndromes associated with myoclonus.

Authors:  Danielle M Andrade; Clement Hamani; Berge A Minassian
Journal:  Expert Opin Pharmacother       Date:  2009-07       Impact factor: 3.889

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.